|
whole-exome sequencing |
24 |
|
nasopharyngeal carcinoma |
23 |
|
aged |
15 |
|
advanced cancer |
14 |
|
cancer susceptibility genes |
13 |
|
early-age onset |
13 |
|
gastric cancer |
13 |
|
mst1r |
13 |
|
apobec-mediated signature |
12 |
|
nf-Îşb signaling |
12 |
|
somatic mutation landscape |
12 |
|
arhgap fusions |
10 |
|
biobank |
10 |
|
cancer center |
10 |
|
cancer patient |
10 |
|
cancer radiotherapy |
10 |
|
chemoradiotherapy |
10 |
|
drug screening |
10 |
|
ebv genome |
10 |
|
heterogeneity |
10 |
|
intensity-modulated radiation therapy |
10 |
|
organoid culture |
10 |
|
rhoa mutations |
10 |
|
transcriptome sequencing |
10 |
|
leucocyte telomere length |
9 |
|
medical sciences |
9 |
|
neoadjuvant therapy |
9 |
|
npc risk |
9 |
|
plasma ebv dna |
9 |
|
prognostic marker |
9 |
|
survival |
9 |
|
telomere biology |
9 |
|
chemotherapy |
8 |
|
circulating neoplastic cell |
8 |
|
circulating tumor dna |
8 |
|
liquid biopsy |
8 |
|
oncology |
8 |
|
recursive partitioning analysis |
8 |
|
stage classification |
8 |
|
survival prediction |
8 |
|
adjuvant chemotherapy |
7 |
|
adolescent |
7 |
|
adult |
7 |
|
cancer adjuvant therapy |
7 |
|
cancer chemotherapy |
7 |
|
cancer prognosis |
7 |
|
cancer screening |
7 |
|
cell-free dna |
7 |
|
circulating tumor cells |
7 |
|
ctc enumeration |
7 |
|
esophageal cancer |
7 |
|
evidence based medicine |
7 |
|
longitudinal real-time monitoring |
7 |
|
non-invasive biomarker |
7 |
|
non-metastatic |
7 |
|
oesophageal cancer |
7 |
|
oesophageal squamous cell carcinoma |
7 |
|
oesophagectomy |
7 |
|
prognostic factors |
7 |
|
radiotherapy |
7 |
|
concurrent chemoradiotherapy |
6 |
|
esophagectomy |
6 |
|
metastatic |
6 |
|
non-small cell lung cancer |
6 |
|
palliative care |
6 |
|
positron emission tomography |
6 |
|
prognostic factor |
6 |
|
aetiology |
5 |
|
chinese |
5 |
|
half-life clearance |
5 |
|
her2+ breast cancer |
5 |
|
her2-targeted therapy |
5 |
|
immunotherapy |
5 |
|
local clinical remission |
5 |
|
metastatic brain tumours |
5 |
|
metastatic colorectal cancer |
5 |
|
metronomic |
5 |
|
oral cyclophosphamide |
5 |
|
palliative |
5 |
|
plasma epstein–barr virus deoxyribonucleic acid |
5 |
|
post-treatment plasma ebv dna |
5 |
|
prognostication |
5 |
|
radiation therapy |
5 |
|
radiology and nuclear medicine |
5 |
|
recurrent |
5 |
|
surgery |
5 |
|
systemic treatment |
5 |
|
tyrosine kinase inhibitor |
5 |
|
5-fluorouracil |
4 |
|
cancer outcomes |
4 |
|
cancer site-standardized relative survival |
4 |
|
capecitabine |
4 |
|
cetuximab |
4 |
|
cisplatin |
4 |
|
dynamic contrast enhanced |
4 |
|
esophageal squamous cell carcinoma |
4 |
|
global health |
4 |
|
health economics |
4 |
|
immune checkpoint inhibitor |
4 |
|
intravoxel incoherent motion |
4 |
|
magnetic resonance imaging |
4 |
|
neoplasm metastasis |
4 |
|
s-1 (combination) |
4 |
|
squamous cell carcinoma |
4 |
|
stomach neoplasms |
4 |
|
target therapy |
4 |
|
tumor staging |
4 |
|
accuracy |
3 |
|
active surveillance |
3 |
|
brachytherapy |
3 |
|
cervical esophageal cancer |
3 |
|
cytology and histology |
3 |
|
do-not-resuscitate |
3 |
|
dysphagia |
3 |
|
end of life |
3 |
|
high dose rate endorectal brachytherapy |
3 |
|
intensity modulated radiotherapy |
3 |
|
international atomic energy agency (iaea) |
3 |
|
laryngeal preservation |
3 |
|
low-middle income countries |
3 |
|
medically inoperable |
3 |
|
nasopharyngeal cancer (npc) |
3 |
|
nasopharyngectomy |
3 |
|
neoadjuvant chemoradiotherapy |
3 |
|
oncology medical sciences |
3 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
3 |
|
radiotherapy access |
3 |
|
rectal brachytherapy |
3 |
|
rectal cancer |
3 |
|
standard of care |
3 |
|
targeted therapy |
3 |
|
toxicity |
3 |
|
adenocarcinoma |
2 |
|
bmp antagonist |
2 |
|
breast cancer |
2 |
|
cancer |
2 |
|
cancer incidence |
2 |
|
cancer mortality |
2 |
|
cancer survival |
2 |
|
chinese herbal medicine |
2 |
|
communication |
2 |
|
docetaxel |
2 |
|
esophageal |
2 |
|
esophageal adenocarcinoma |
2 |
|
esophagogastric |
2 |
|
esophagogastric junction adenocarcinoma |
2 |
|
gastric cancer progression |
2 |
|
hepatotoxicity |
2 |
|
hong kong |
2 |
|
jnk inhibition |
2 |
|
liver toxicity |
2 |
|
neoadjuvant |
2 |
|
perioperative |
2 |
|
preoperative |
2 |
|
refractory |
2 |
|
regorafenib |
2 |
|
sostdc1 |
2 |
|
terminal care |
2 |
|
trifluridine/tipiracil (tas-102) |
2 |
|
chemotherapy, adjuvant |
1 |
|
colorectal neoplasms |
1 |
|
induction chemotherapy |
1 |
|
oxaliplatin |
1 |
|
receptor, epidermal growth factor |
1 |
|
rectal neoplasms |
1 |
|
vascular epidermal growth factor |
1 |
